Healthcare & Medical Devices Global On demand · 24-48h

Global Mycotoxin Testing Market Strategic Research Report

Global Mycotoxin Testing Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Mycotoxin Testing Market
$1.47B2025
7.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Chromatography-based Testing, Immunoassay-based Testing, Biosensor and Spectroscopic Testing

By Application: Food and Beverage Manufacturers, Feed and Agricultural Producers, Government and Third-party Testing Laboratories, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Neogen Corporation, Romer Labs Division Holding GmbH, R-Biopharm AG, Charm Sciences, Inc., Hygiena LLC, Eurofins Technologies, Vicam, Beacon Analytical Systems, Inc., Helica Biosystems, Inc., Gold Standard Diagnostics, ProGnosis Biotech S.A., Ring Biotechnology Co., Ltd., Practical Japan Inc., Shenzhen Bioeasy Biotechnology Co., Ltd., Beijing Kwinbon Biotechnology Co., Ltd., Meizheng Bio-Tech Co., Ltd., Hangzhou AllTest Biotech Co., Ltd., Beijing WDWK Biotechnology Co., Ltd., Shandong Lvdu Bio-Sciences & Technology Co., Ltd., Guangzhou Wondfo Biotech Co., Ltd., Hangzhou CHNSpec Technology Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 145 pages
Market size 2025
$1.47B
Billion USD
Forecast CAGR
7.5%
2025-2032
Forecast 2032
$2.4B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Mycotoxin Testing market size is predicted to grow from US$ 1,471 million in 2025 to US$ 2,436 million in 2032; it is expected to grow at a CAGR of 7.5% from 2026 to 2032.

The gross profit margin of major companies was approximately 38%–60%.

Global testing capacity was approximately 34,000 thousand tests in 2025.

Mycotoxin Testing detects and quantifies aflatoxins, ochratoxins, fumonisins, deoxynivalenol, zearalenone, and related fungal toxins in food, feed, and agricultural products. Methods include chromatography, mass spectrometry, immunoassays, and rapid test strips. The scope excludes fungal species identification, pesticide residue testing, microbial testing, decontamination treatment, and unrelated food-safety services.

The industrial chain includes upstream antibodies, standards, solvents, columns, test strips, sampling products, and analytical instruments. Midstream covers reagent production, sampling, extraction, separation, detection, data interpretation, and laboratory certification. Downstream users include grain processors, food manufacturers, feed companies, agricultural traders, inspection agencies, laboratories, retailers, and regulators.

Mycotoxin Testing comprises instruments, kits, consumables, and laboratory services used to detect toxic fungal metabolites in grains, nuts, feed, dairy products, spices, beverages, and processed foods. Major targets include aflatoxins, deoxynivalenol, fumonisins, ochratoxin A, zearalenone, and patulin. Common technologies include chromatography, mass spectrometry, enzyme-linked immunoassays, lateral-flow tests, fluorescence analysis, and biosensors. The market is developing toward multi-toxin detection, shorter testing times, portable on-site analysis, automated sample preparation, and cloud-based data management. Demand is driven by stricter food and feed safety regulations, climate-related changes in fungal contamination, growth in international agricultural trade, and increased quality-control requirements among food manufacturers and retailers. Rapid test kits are expanding in procurement, storage, and processing environments, while confirmatory laboratories increasingly use high-resolution analytical platforms. Market growth may be limited by uneven regulatory standards, complicated sample preparation, matrix interference, skilled-labor requirements, and the cost of advanced analytical equipment.

This report presents a comprehensive overview of the global Mycotoxin Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Chromatography-based Testing
  • Immunoassay-based Testing
  • Biosensor and Spectroscopic Testing

Segment by Testing Format

  • Laboratory Instrument Testing
  • Rapid Test Kit Testing
  • On-site Portable Testing

Segment by Detection Limit

  • High-sensitivity(≤0.1 μg/kg)
  • Medium-sensitivity(>0.1–5 μg/kg)
  • Standard-sensitivity(>5 μg/kg)

Segment by players, this report covers

  • Neogen Corporation
  • Romer Labs Division Holding GmbH
  • R-Biopharm AG
  • Charm Sciences, Inc.
  • Hygiena LLC
  • Eurofins Technologies
  • Vicam
  • Beacon Analytical Systems, Inc.
  • Helica Biosystems, Inc.
  • Gold Standard Diagnostics
  • ProGnosis Biotech S.A.
  • Ring Biotechnology Co., Ltd.
  • Practical Japan Inc.
  • Shenzhen Bioeasy Biotechnology Co., Ltd.
  • Beijing Kwinbon Biotechnology Co., Ltd.
  • Meizheng Bio-Tech Co., Ltd.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Beijing WDWK Biotechnology Co., Ltd.
  • Shandong Lvdu Bio-Sciences & Technology Co., Ltd.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hangzhou CHNSpec Technology Co., Ltd.

Segment by Application

  • Food and Beverage Manufacturers
  • Feed and Agricultural Producers
  • Government and Third-party Testing Laboratories
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Mycotoxin Testing market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Food and Beverage Manufacturers, Feed and Agricultural Producers, Government and Third-party Testing Laboratories evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Mycotoxin Testing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.47B
2025
Forecast
$2.4B
2032
CAGR
7.5%
2025–2032
Regions
5
global
Key companies
Neogen CorporationRomer Labs Division Holding GmbHR-Biopharm AGCharm Sciences, Inc.Hygiena LLCEurofins TechnologiesVicamBeacon Analytical Systems, Inc.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Chromatography-based TestingImmunoassay-based TestingBiosensor and Spectroscopic Testing
By Application
Food and Beverage ManufacturersFeed and Agricultural ProducersGovernment and Third-party Testing LaboratoriesOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Chromatography-based Testing
  • 3.1.3 Immunoassay-based Testing
  • 3.1.4 Biosensor and Spectroscopic Testing
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Food and Beverage Manufacturers
  • 4.1.3 Feed and Agricultural Producers
  • 4.1.4 Government and Third-party Testing Laboratories
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Neogen Corporation
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Romer Labs Division Holding GmbH
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 R-Biopharm AG
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Charm Sciences, Inc.
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Hygiena LLC
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Eurofins Technologies
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Vicam
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Beacon Analytical Systems, Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Helica Biosystems, Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Gold Standard Diagnostics
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 ProGnosis Biotech S.A.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Ring Biotechnology Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Practical Japan Inc.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Shenzhen Bioeasy Biotechnology Co., Ltd.
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Beijing Kwinbon Biotechnology Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Meizheng Bio-Tech Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Hangzhou AllTest Biotech Co., Ltd.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Beijing WDWK Biotechnology Co., Ltd.
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Shandong Lvdu Bio-Sciences & Technology Co., Ltd.
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Guangzhou Wondfo Biotech Co., Ltd.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Hangzhou CHNSpec Technology Co., Ltd.
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Mycotoxin Testing market size?
The global Mycotoxin Testing market is estimated at US$ 1.47 billion in 2025 (base year) and is projected to reach US$ 2.44 billion by 2032.
What growth rate is expected for the Mycotoxin Testing market through 2032?
The market is expected to grow at a CAGR of 7.5% from 2026 to 2032, expanding from US$ 1.47 billion in 2025 to US$ 2.44 billion in 2032, roughly 1.7 times its base-year value.
How is Mycotoxin Testing defined?
The gross profit margin of major companies was approximately 38%–60%.
What are the main segments of the Mycotoxin Testing market by type?
By type, the market is segmented into Chromatography-based Testing, Immunoassay-based Testing and Biosensor and Spectroscopic Testing.
Which applications drive demand in the Mycotoxin Testing market?
Key applications covered include Food and Beverage Manufacturers, Feed and Agricultural Producers, Government and Third-party Testing Laboratories and Other.
Who are the key players in the Mycotoxin Testing market?
Key players profiled include Neogen Corporation, Romer Labs Division Holding GmbH, R-Biopharm AG, Charm Sciences, Hygiena LLC, Eurofins Technologies, Vicam and Beacon Analytical Systems, among 21 companies covered in total.
Which regions and countries are covered for Mycotoxin Testing?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Mycotoxin Testing market?
Demand is driven by stricter food and feed safety regulations, climate-related changes in fungal contamination, growth in international agricultural trade, and increased quality-control requirements among food manufacturers and retailers.
Who should buy the Mycotoxin Testing market report?
The report is intended for manufacturers and solution providers, distributors and end users in Food and Beverage Manufacturers, Feed and Agricultural Producers and Government and Third-party Testing Laboratories, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Mycotoxin Testing market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.